我们所有人研究计划中他汀类药物的使用与青光眼之间的关系。

IF 2.8 Q1 OPHTHALMOLOGY Ophthalmology. Glaucoma Pub Date : 2024-11-01 DOI:10.1016/j.ogla.2024.07.008
Samuel Y. Lee BA , Megan E. Paul BA , Anne L. Coleman MD, PhD , Ken Kitayama MD, PhD , Fei Yu PhD , Deyu Pan MS , Victoria L. Tseng MD, PhD
{"title":"我们所有人研究计划中他汀类药物的使用与青光眼之间的关系。","authors":"Samuel Y. Lee BA ,&nbsp;Megan E. Paul BA ,&nbsp;Anne L. Coleman MD, PhD ,&nbsp;Ken Kitayama MD, PhD ,&nbsp;Fei Yu PhD ,&nbsp;Deyu Pan MS ,&nbsp;Victoria L. Tseng MD, PhD","doi":"10.1016/j.ogla.2024.07.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate associations between statin use and glaucoma in the 2017 to 2022 <em>All of Us</em> (<em>AoU</em>) Research Program.</div></div><div><h3>Design</h3><div>Cross-sectional, population-based.</div></div><div><h3>Participants</h3><div>79 742 adult participants aged ≥40 years with hyperlipidemia and with electronic health record (EHR) data in the <em>AoU</em> database.</div></div><div><h3>Methods</h3><div>Hyperlipidemia, glaucoma status, and statin use were defined by diagnoses and medication information in EHR data collected by <em>AoU</em>. Logistic regression analysis was performed to evaluate the association between statin use and glaucoma likelihood. Logistic regression modeling was used to examine associations between glaucoma and all covariates included in adjusted analysis. Serum low-density lipoprotein cholesterol (LDL-C) was used to assess hyperlipidemia severity. Analyses stratified by LDL-C level and age were performed.</div></div><div><h3>Main Outcome Measures</h3><div>Any glaucoma as defined by International Classification of Diseases codes found in EHR data.</div></div><div><h3>Results</h3><div>Of 79 742 individuals with hyperlipidemia in <em>AoU</em>, there were 6365 (8.0%) statin users. Statin use was associated with increased glaucoma prevalence when compared with statin nonuse (adjusted odds ratio [aOR]: 1.13, 95% confidence interval [CI]: 1.01–1.26). Higher serum levels of LDL-C were associated with increased odds of glaucoma (aOR: 1.003, 95% CI: 1.003, 1.004). Statin users had significantly higher LDL-C levels compared to nonusers (144.9 mg/dL versus 136.3 mg/dL, <em>P</em> value &lt; 0.001). Analysis stratified by LDL-C identified positive associations between statin use and prevalence of glaucoma among those with optimal (aOR = 1.39, 95% CI = 1.05–1.82) and high (aOR = 1.37, 95% CI = 1.09–1.70) LDL-C levels. Age-stratified analysis showed a positive association between statin use and prevalence of glaucoma in individuals aged 60 to 69 years (aOR = 1.28, 95% CI = 1.05–1.56).</div></div><div><h3>Conclusions</h3><div>Statin use was associated with increased glaucoma likelihood in the overall adult <em>AoU</em> population with hyperlipidemia, in individuals with optimal or high LDL-C levels, and in individuals 60 to 69 years old. Findings suggest that statin use may be an independent risk factor for glaucoma, which may furthermore be affected by one’s lipid profile and age.</div></div><div><h3>Financial Disclosures</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"7 6","pages":"Pages 563-571"},"PeriodicalIF":2.8000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Associations between Statin Use and Glaucoma in the All of Us Research Program\",\"authors\":\"Samuel Y. Lee BA ,&nbsp;Megan E. Paul BA ,&nbsp;Anne L. Coleman MD, PhD ,&nbsp;Ken Kitayama MD, PhD ,&nbsp;Fei Yu PhD ,&nbsp;Deyu Pan MS ,&nbsp;Victoria L. Tseng MD, PhD\",\"doi\":\"10.1016/j.ogla.2024.07.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>To investigate associations between statin use and glaucoma in the 2017 to 2022 <em>All of Us</em> (<em>AoU</em>) Research Program.</div></div><div><h3>Design</h3><div>Cross-sectional, population-based.</div></div><div><h3>Participants</h3><div>79 742 adult participants aged ≥40 years with hyperlipidemia and with electronic health record (EHR) data in the <em>AoU</em> database.</div></div><div><h3>Methods</h3><div>Hyperlipidemia, glaucoma status, and statin use were defined by diagnoses and medication information in EHR data collected by <em>AoU</em>. Logistic regression analysis was performed to evaluate the association between statin use and glaucoma likelihood. Logistic regression modeling was used to examine associations between glaucoma and all covariates included in adjusted analysis. Serum low-density lipoprotein cholesterol (LDL-C) was used to assess hyperlipidemia severity. Analyses stratified by LDL-C level and age were performed.</div></div><div><h3>Main Outcome Measures</h3><div>Any glaucoma as defined by International Classification of Diseases codes found in EHR data.</div></div><div><h3>Results</h3><div>Of 79 742 individuals with hyperlipidemia in <em>AoU</em>, there were 6365 (8.0%) statin users. Statin use was associated with increased glaucoma prevalence when compared with statin nonuse (adjusted odds ratio [aOR]: 1.13, 95% confidence interval [CI]: 1.01–1.26). Higher serum levels of LDL-C were associated with increased odds of glaucoma (aOR: 1.003, 95% CI: 1.003, 1.004). Statin users had significantly higher LDL-C levels compared to nonusers (144.9 mg/dL versus 136.3 mg/dL, <em>P</em> value &lt; 0.001). Analysis stratified by LDL-C identified positive associations between statin use and prevalence of glaucoma among those with optimal (aOR = 1.39, 95% CI = 1.05–1.82) and high (aOR = 1.37, 95% CI = 1.09–1.70) LDL-C levels. Age-stratified analysis showed a positive association between statin use and prevalence of glaucoma in individuals aged 60 to 69 years (aOR = 1.28, 95% CI = 1.05–1.56).</div></div><div><h3>Conclusions</h3><div>Statin use was associated with increased glaucoma likelihood in the overall adult <em>AoU</em> population with hyperlipidemia, in individuals with optimal or high LDL-C levels, and in individuals 60 to 69 years old. Findings suggest that statin use may be an independent risk factor for glaucoma, which may furthermore be affected by one’s lipid profile and age.</div></div><div><h3>Financial Disclosures</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>\",\"PeriodicalId\":19519,\"journal\":{\"name\":\"Ophthalmology. Glaucoma\",\"volume\":\"7 6\",\"pages\":\"Pages 563-571\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmology. Glaucoma\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2589419624001376\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Glaucoma","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589419624001376","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:在2017-2022年 "我们所有人"(AoU)研究计划中调查他汀类药物的使用与青光眼之间的关联:横断面,基于人群:79,742名年龄≥40岁、患有高脂血症且在AoU数据库中有电子健康记录(EHR)数据的成年参与者。方法:根据AoU收集的EHR数据中的诊断和用药信息来定义高脂血症、青光眼状态和他汀类药物的使用。采用逻辑回归分析评估他汀类药物的使用与青光眼可能性之间的关联。逻辑回归模型用于检查青光眼与调整分析中包含的所有协变量之间的关系。血清低密度脂蛋白胆固醇(LDL-C)用于评估高脂血症的严重程度。根据低密度脂蛋白胆固醇水平和年龄进行分层分析:根据电子病历数据中的国际疾病分类(ICD)代码定义的任何青光眼:在澳大地区的79742名高脂血症患者中,有6365人(8.0%)使用他汀类药物。与不使用他汀类药物相比,使用他汀类药物与青光眼患病率增加有关(调整赔率比 [aOR]:1.13,95% 置信区间 [CI]:1.01-1.26)。血清低密度脂蛋白胆固醇水平越高,患青光眼的几率越大(aOR:1.003,95% CI:1.003,1.004)。他汀类药物使用者的低密度脂蛋白胆固醇水平明显高于非使用者(144.9 mg/dL 对 136.3 mg/dL,P 值 < 0.001)。通过对低密度脂蛋白胆固醇进行分层分析,发现在最佳(aOR = 1.39,95% CI = 1.05-1.82)和高(aOR = 1.37,95% CI = 1.09-1.70)低密度脂蛋白胆固醇水平人群中,他汀类药物的使用与青光眼患病率呈正相关。年龄分层分析显示,他汀类药物的使用与 60-69 岁人群的青光眼患病率呈正相关(aOR = 1.28,95% CI = 1.05-1.56):结论:他汀类药物的使用与患有高脂血症的澳大拉西亚成年人群、低密度脂蛋白胆固醇水平处于最佳或较高水平的人群以及 60-69 岁人群患青光眼的可能性增加有关。研究结果表明,他汀类药物的使用可能是青光眼的一个独立风险因素,而且还可能受到血脂状况和年龄的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Associations between Statin Use and Glaucoma in the All of Us Research Program

Purpose

To investigate associations between statin use and glaucoma in the 2017 to 2022 All of Us (AoU) Research Program.

Design

Cross-sectional, population-based.

Participants

79 742 adult participants aged ≥40 years with hyperlipidemia and with electronic health record (EHR) data in the AoU database.

Methods

Hyperlipidemia, glaucoma status, and statin use were defined by diagnoses and medication information in EHR data collected by AoU. Logistic regression analysis was performed to evaluate the association between statin use and glaucoma likelihood. Logistic regression modeling was used to examine associations between glaucoma and all covariates included in adjusted analysis. Serum low-density lipoprotein cholesterol (LDL-C) was used to assess hyperlipidemia severity. Analyses stratified by LDL-C level and age were performed.

Main Outcome Measures

Any glaucoma as defined by International Classification of Diseases codes found in EHR data.

Results

Of 79 742 individuals with hyperlipidemia in AoU, there were 6365 (8.0%) statin users. Statin use was associated with increased glaucoma prevalence when compared with statin nonuse (adjusted odds ratio [aOR]: 1.13, 95% confidence interval [CI]: 1.01–1.26). Higher serum levels of LDL-C were associated with increased odds of glaucoma (aOR: 1.003, 95% CI: 1.003, 1.004). Statin users had significantly higher LDL-C levels compared to nonusers (144.9 mg/dL versus 136.3 mg/dL, P value < 0.001). Analysis stratified by LDL-C identified positive associations between statin use and prevalence of glaucoma among those with optimal (aOR = 1.39, 95% CI = 1.05–1.82) and high (aOR = 1.37, 95% CI = 1.09–1.70) LDL-C levels. Age-stratified analysis showed a positive association between statin use and prevalence of glaucoma in individuals aged 60 to 69 years (aOR = 1.28, 95% CI = 1.05–1.56).

Conclusions

Statin use was associated with increased glaucoma likelihood in the overall adult AoU population with hyperlipidemia, in individuals with optimal or high LDL-C levels, and in individuals 60 to 69 years old. Findings suggest that statin use may be an independent risk factor for glaucoma, which may furthermore be affected by one’s lipid profile and age.

Financial Disclosures

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Ophthalmology. Glaucoma
Ophthalmology. Glaucoma OPHTHALMOLOGY-
CiteScore
4.80
自引率
6.90%
发文量
140
审稿时长
46 days
期刊最新文献
Reply Editorial Board Contents Posterior Capsular Pigment Deposition in a Case of Pigmentary Glaucoma Iridoschisis: The Shredded Iris
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1